Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 28 | 2021 | 43 | 8.690 |
Why?
|
| Antiviral Agents | 30 | 2021 | 71 | 7.240 |
Why?
|
| Hepatitis C | 19 | 2022 | 43 | 6.450 |
Why?
|
| Liver Diseases | 13 | 2022 | 34 | 5.180 |
Why?
|
| Hepacivirus | 23 | 2022 | 32 | 4.590 |
Why?
|
| Pregnancy Complications | 8 | 2022 | 48 | 3.840 |
Why?
|
| Liver Transplantation | 9 | 2023 | 92 | 3.760 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 5 | 2024 | 6 | 2.130 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2020 | 14 | 1.850 |
Why?
|
| Pregnancy | 13 | 2022 | 331 | 1.700 |
Why?
|
| Liver Cirrhosis | 12 | 2024 | 44 | 1.690 |
Why?
|
| Humans | 66 | 2024 | 27144 | 1.500 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2020 | 9 | 1.500 |
Why?
|
| Ribavirin | 8 | 2016 | 9 | 1.350 |
Why?
|
| Coinfection | 4 | 2023 | 21 | 1.280 |
Why?
|
| Sulfonamides | 7 | 2020 | 44 | 1.210 |
Why?
|
| Hepatitis B | 5 | 2019 | 12 | 1.180 |
Why?
|
| HIV Infections | 4 | 2021 | 475 | 1.130 |
Why?
|
| United States | 18 | 2022 | 2060 | 1.030 |
Why?
|
| Female | 35 | 2024 | 15258 | 1.030 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2024 | 5 | 1.030 |
Why?
|
| Liver Neoplasms | 3 | 2022 | 103 | 0.970 |
Why?
|
| Carbamates | 9 | 2020 | 9 | 0.940 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2022 | 25 | 0.920 |
Why?
|
| Quinoxalines | 5 | 2020 | 6 | 0.880 |
Why?
|
| Interferon-alpha | 4 | 2012 | 30 | 0.880 |
Why?
|
| Polyethylene Glycols | 4 | 2012 | 42 | 0.870 |
Why?
|
| Hepatitis D | 1 | 2023 | 1 | 0.850 |
Why?
|
| Drug Therapy, Combination | 12 | 2021 | 168 | 0.780 |
Why?
|
| Gastroenterology | 3 | 2017 | 9 | 0.780 |
Why?
|
| Treatment Outcome | 19 | 2021 | 3525 | 0.780 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2021 | 34 | 0.770 |
Why?
|
| Living Donors | 1 | 2021 | 17 | 0.730 |
Why?
|
| Prejudice | 1 | 2021 | 34 | 0.730 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 22 | 0.690 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 110 | 0.680 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 37 | 0.680 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 25 | 0.680 |
Why?
|
| Patient Selection | 1 | 2021 | 197 | 0.670 |
Why?
|
| Benzimidazoles | 3 | 2019 | 9 | 0.670 |
Why?
|
| Kidney Transplantation | 2 | 2018 | 119 | 0.670 |
Why?
|
| Genotype | 10 | 2017 | 344 | 0.650 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2019 | 1 | 0.630 |
Why?
|
| Viral Load | 5 | 2016 | 75 | 0.620 |
Why?
|
| Algorithms | 2 | 2020 | 352 | 0.610 |
Why?
|
| Sofosbuvir | 6 | 2019 | 6 | 0.610 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 6 | 2019 | 6 | 0.610 |
Why?
|
| Obesity | 1 | 2021 | 309 | 0.600 |
Why?
|
| Fear | 1 | 2018 | 47 | 0.580 |
Why?
|
| Cholestasis, Intrahepatic | 3 | 2019 | 4 | 0.580 |
Why?
|
| Adult | 19 | 2021 | 7910 | 0.580 |
Why?
|
| Liver | 3 | 2022 | 148 | 0.570 |
Why?
|
| Cyclopropanes | 5 | 2020 | 13 | 0.530 |
Why?
|
| Drugs, Generic | 1 | 2016 | 1 | 0.520 |
Why?
|
| Antacids | 1 | 2016 | 1 | 0.520 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 11 | 0.510 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2016 | 3 | 0.510 |
Why?
|
| Sustained Virologic Response | 6 | 2021 | 6 | 0.510 |
Why?
|
| Virology | 1 | 2015 | 1 | 0.500 |
Why?
|
| Middle Aged | 19 | 2021 | 9021 | 0.500 |
Why?
|
| Length of Stay | 2 | 2016 | 319 | 0.460 |
Why?
|
| Patient Readmission | 1 | 2016 | 130 | 0.460 |
Why?
|
| Liver Function Tests | 3 | 2022 | 21 | 0.460 |
Why?
|
| Young Adult | 9 | 2021 | 2025 | 0.450 |
Why?
|
| Heart Failure | 1 | 2016 | 149 | 0.440 |
Why?
|
| Prevalence | 3 | 2023 | 457 | 0.430 |
Why?
|
| Risk Factors | 6 | 2023 | 2331 | 0.420 |
Why?
|
| Preventive Health Services | 1 | 2013 | 13 | 0.420 |
Why?
|
| Advisory Committees | 1 | 2013 | 20 | 0.420 |
Why?
|
| Prognosis | 5 | 2022 | 804 | 0.420 |
Why?
|
| Patient Reported Outcome Measures | 6 | 2021 | 511 | 0.420 |
Why?
|
| Health Policy | 1 | 2013 | 41 | 0.410 |
Why?
|
| Periodicals as Topic | 2 | 2023 | 39 | 0.410 |
Why?
|
| Mass Screening | 4 | 2021 | 173 | 0.400 |
Why?
|
| Male | 21 | 2021 | 14810 | 0.400 |
Why?
|
| Disease Management | 2 | 2016 | 104 | 0.390 |
Why?
|
| Hepatitis C Antibodies | 2 | 2022 | 4 | 0.380 |
Why?
|
| Retrospective Studies | 8 | 2024 | 3544 | 0.380 |
Why?
|
| Proline | 4 | 2019 | 10 | 0.350 |
Why?
|
| Lactams, Macrocyclic | 4 | 2019 | 5 | 0.350 |
Why?
|
| Imidazoles | 4 | 2020 | 62 | 0.350 |
Why?
|
| RNA, Viral | 4 | 2022 | 48 | 0.350 |
Why?
|
| Macrocyclic Compounds | 4 | 2019 | 4 | 0.340 |
Why?
|
| Pregnancy Outcome | 2 | 2021 | 21 | 0.330 |
Why?
|
| Drug Resistance, Viral | 4 | 2017 | 14 | 0.330 |
Why?
|
| Aged | 13 | 2020 | 9076 | 0.300 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 161 | 0.300 |
Why?
|
| Cost of Illness | 2 | 2023 | 50 | 0.300 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2008 | 2 | 0.290 |
Why?
|
| Motivation | 3 | 2023 | 89 | 0.290 |
Why?
|
| Fatty Liver | 2 | 2019 | 26 | 0.280 |
Why?
|
| Medication Adherence | 2 | 2019 | 52 | 0.280 |
Why?
|
| Recombinant Proteins | 4 | 2012 | 183 | 0.270 |
Why?
|
| Cohort Studies | 5 | 2021 | 1901 | 0.260 |
Why?
|
| Societies, Medical | 2 | 2017 | 123 | 0.250 |
Why?
|
| Adolescent | 4 | 2020 | 2178 | 0.250 |
Why?
|
| Benzofurans | 3 | 2020 | 5 | 0.250 |
Why?
|
| Graft Rejection | 2 | 2018 | 69 | 0.240 |
Why?
|
| Valine | 4 | 2019 | 5 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 4 | 2021 | 126 | 0.220 |
Why?
|
| Incidence | 2 | 2020 | 763 | 0.220 |
Why?
|
| Pyrrolidines | 3 | 2018 | 11 | 0.220 |
Why?
|
| Hepatitis Delta Virus | 1 | 2023 | 1 | 0.210 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 1 | 0.210 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2023 | 5 | 0.210 |
Why?
|
| Amides | 2 | 2020 | 15 | 0.210 |
Why?
|
| Benzamides | 1 | 2023 | 15 | 0.210 |
Why?
|
| Vaccination | 1 | 2023 | 35 | 0.200 |
Why?
|
| Chronic Disease | 3 | 2020 | 423 | 0.200 |
Why?
|
| Ritonavir | 3 | 2019 | 3 | 0.200 |
Why?
|
| Uracil | 3 | 2019 | 4 | 0.200 |
Why?
|
| Mastocytosis, Systemic | 1 | 2022 | 7 | 0.200 |
Why?
|
| RNA | 1 | 2022 | 40 | 0.200 |
Why?
|
| Risk Assessment | 2 | 2018 | 628 | 0.200 |
Why?
|
| Fibrosis | 1 | 2022 | 31 | 0.190 |
Why?
|
| Selection Bias | 1 | 2021 | 7 | 0.190 |
Why?
|
| Graft Survival | 2 | 2019 | 97 | 0.190 |
Why?
|
| Fertility | 1 | 2021 | 19 | 0.180 |
Why?
|
| Aminoisobutyric Acids | 2 | 2018 | 2 | 0.180 |
Why?
|
| Leucine | 2 | 2018 | 11 | 0.180 |
Why?
|
| Critical Care | 1 | 2022 | 122 | 0.180 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 4828 | 0.180 |
Why?
|
| World Health Organization | 1 | 2020 | 9 | 0.180 |
Why?
|
| Tissue Donors | 1 | 2021 | 79 | 0.170 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 12 | 0.170 |
Why?
|
| Pandemics | 1 | 2022 | 241 | 0.170 |
Why?
|
| Anilides | 2 | 2019 | 7 | 0.170 |
Why?
|
| 2-Naphthylamine | 2 | 2019 | 3 | 0.170 |
Why?
|
| Recurrence | 2 | 2011 | 309 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2020 | 82 | 0.170 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 146 | 0.170 |
Why?
|
| Consensus | 2 | 2021 | 92 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2019 | 1778 | 0.160 |
Why?
|
| Drug and Narcotic Control | 2 | 2016 | 3 | 0.160 |
Why?
|
| Forecasting | 1 | 2019 | 92 | 0.160 |
Why?
|
| United States Food and Drug Administration | 2 | 2016 | 18 | 0.160 |
Why?
|
| Hyperemesis Gravidarum | 1 | 2019 | 1 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 260 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2019 | 60 | 0.160 |
Why?
|
| Internationality | 1 | 2018 | 20 | 0.150 |
Why?
|
| Transplant Recipients | 1 | 2018 | 22 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 331 | 0.140 |
Why?
|
| Infant, Newborn | 1 | 2019 | 562 | 0.140 |
Why?
|
| Drug Substitution | 1 | 2017 | 4 | 0.140 |
Why?
|
| Critical Pathways | 1 | 2017 | 20 | 0.140 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 892 | 0.130 |
Why?
|
| Psychometrics | 1 | 2018 | 218 | 0.130 |
Why?
|
| Patient Participation | 1 | 2017 | 47 | 0.130 |
Why?
|
| Counterfeit Drugs | 1 | 2016 | 1 | 0.130 |
Why?
|
| Drug Approval | 1 | 2016 | 5 | 0.130 |
Why?
|
| Safety | 1 | 2016 | 37 | 0.130 |
Why?
|
| Commerce | 1 | 2016 | 12 | 0.130 |
Why?
|
| Canada | 1 | 2016 | 46 | 0.130 |
Why?
|
| Quality Control | 1 | 2016 | 27 | 0.130 |
Why?
|
| Ascites | 1 | 2016 | 2 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 1152 | 0.130 |
Why?
|
| Hospitalization | 2 | 2016 | 303 | 0.130 |
Why?
|
| Paracentesis | 1 | 2016 | 4 | 0.130 |
Why?
|
| Interferons | 1 | 2016 | 9 | 0.130 |
Why?
|
| Fraud | 1 | 2016 | 21 | 0.130 |
Why?
|
| Eclampsia | 1 | 2016 | 1 | 0.130 |
Why?
|
| HELLP Syndrome | 1 | 2016 | 1 | 0.130 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 7 | 0.130 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2016 | 131 | 0.130 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 24 | 0.120 |
Why?
|
| Drug Interactions | 1 | 2015 | 35 | 0.120 |
Why?
|
| Directive Counseling | 1 | 2015 | 11 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 127 | 0.120 |
Why?
|
| Benchmarking | 1 | 2015 | 33 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2015 | 110 | 0.120 |
Why?
|
| Benzazepines | 1 | 2015 | 4 | 0.120 |
Why?
|
| Isoquinolines | 1 | 2015 | 12 | 0.120 |
Why?
|
| Indoles | 1 | 2015 | 33 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2017 | 159 | 0.120 |
Why?
|
| Time Factors | 2 | 2016 | 1438 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 291 | 0.110 |
Why?
|
| Phenotype | 1 | 2015 | 312 | 0.110 |
Why?
|
| Hospitalists | 1 | 2014 | 3 | 0.110 |
Why?
|
| Off-Label Use | 1 | 2014 | 6 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 56 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2014 | 73 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2016 | 214 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2014 | 102 | 0.100 |
Why?
|
| Viral Nonstructural Proteins | 3 | 2017 | 5 | 0.100 |
Why?
|
| Monitoring, Immunologic | 1 | 2012 | 1 | 0.100 |
Why?
|
| Drug Combinations | 3 | 2017 | 34 | 0.100 |
Why?
|
| Comorbidity | 3 | 2018 | 488 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 106 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2010 | 7 | 0.090 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2021 | 22 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 118 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2011 | 127 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2010 | 277 | 0.080 |
Why?
|
| Logistic Models | 1 | 2010 | 397 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 331 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 482 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 1802 | 0.080 |
Why?
|
| Fluorenes | 2 | 2019 | 2 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 216 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 903 | 0.060 |
Why?
|
| Hospital Costs | 2 | 2016 | 60 | 0.060 |
Why?
|
| Pyrroles | 1 | 2022 | 23 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2021 | 13 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2022 | 61 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2019 | 18 | 0.040 |
Why?
|
| Infection Control | 1 | 2021 | 170 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2019 | 35 | 0.040 |
Why?
|
| Insurance, Major Medical | 1 | 2018 | 1 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2018 | 19 | 0.040 |
Why?
|
| Registries | 1 | 2019 | 196 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 42 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2017 | 97 | 0.030 |
Why?
|
| Uridine Monophosphate | 1 | 2017 | 1 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2017 | 19 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 47 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 45 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2018 | 142 | 0.030 |
Why?
|
| Serine Proteases | 1 | 2016 | 7 | 0.030 |
Why?
|
| Career Choice | 1 | 2016 | 26 | 0.030 |
Why?
|
| Internal Medicine | 1 | 2016 | 31 | 0.030 |
Why?
|
| Pain Management | 1 | 2018 | 143 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 32 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 31 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 478 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 119 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 673 | 0.030 |
Why?
|
| Curriculum | 1 | 2016 | 140 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2016 | 141 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 350 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2016 | 210 | 0.030 |
Why?
|
| Drug Industry | 1 | 2014 | 6 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 42 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2014 | 57 | 0.030 |
Why?
|
| Inpatients | 1 | 2014 | 125 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 35 | 0.020 |
Why?
|
| Immunoassay | 1 | 2012 | 38 | 0.020 |
Why?
|
| Probability | 1 | 2012 | 86 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 120 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 928 | 0.020 |
Why?
|